Filing Details

Accession Number:
0001567619-21-018030
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-10-07 16:15:10
Reporting Period:
2021-10-05
Accepted Time:
2021-10-07 16:15:10
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1770787 10X Genomics Inc. TXG Laboratory Analytical Instruments (3826) 455614458
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1786720 Serge Saxonov C/O 10X Genomics, Inc.
6230 Stoneridge Mall Road
Pleasanton CA 94588
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Common Stock Acquisiton 2021-10-05 5,208 $5.04 903,676 No 4 M Direct
Class A Common Stock Acquisiton 2021-10-05 3,460 $11.48 907,136 No 4 M Direct
Class A Common Stock Disposition 2021-10-05 5,024 $142.47 902,112 No 4 S Direct
Class A Common Stock Disposition 2021-10-05 6,056 $143.40 896,056 No 4 S Direct
Class A Common Stock Disposition 2021-10-05 1,900 $144.40 894,156 No 4 S Direct
Class A Common Stock Disposition 2021-10-05 1,720 $145.42 892,436 No 4 S Direct
Class A Common Stock Disposition 2021-10-05 300 $146.12 892,136 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Class A Common Stock Stock Option (right to buy) Disposition 2021-10-05 5,208 $0.00 5,208 $5.04
Class A Common Stock Stock Option (right to buy) Disposition 2021-10-05 3,460 $0.00 3,460 $11.48
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
63,740 2028-11-02 No 4 M Direct
54,670 2029-05-10 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Class A Common Stock 4,498 Indirect See footnote
Class A Common Stock 89,960 Indirect See footnote
Footnotes
  1. The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
  2. This transaction was executed in multiple trades at prices ranging from $141.94 to $142.93. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  3. This transaction was executed in multiple trades at prices ranging from $142.96 to $143.94. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  4. This transaction was executed in multiple trades at prices ranging from $143.96 to $144.95. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  5. This transaction was executed in multiple trades at prices ranging from $144.96 to $145.93. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  6. This transaction was executed in multiple trades at prices ranging from $146.02 to $146.17. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  7. The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.
  8. The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
  9. This option, originally for 250,000 shares, of which 186,260 have been exercised, vested as to 1/48th of the shares on October 1, 2018, and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
  10. This option, originally for 145,786 shares, of which 91,116 have been exercised, vested as to 1/48th of the shares on May 1, 2019, and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.